Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract provides no new clinical results; it discusses the role of surgery and interventional radiotherapy in treating cutaneous squamous cell carcinoma.

Abatacept may help some people with alopecia areata regrow hair.

This study found that 4-aminopyridine, a potassium channel blocker, greatly improves skin wound healing by accelerating wound closure, enhancing tissue regeneration, and promoting hair follicle neogenesis.

This study found that 4-aminopyridine significantly enhanced skin wound healing by accelerating wound closure, improving skin architecture, and promoting hair follicle neogenesis and tissue regeneration.

This study investigated the role of the ABCA4 gene in human keratinocytes and hair follicle stem cells and found that silencing the ABCA4 gene increases the harmful effects of all-trans-retinal on hair follicle stem cells.

This study found that 4-aminopyridine significantly improved skin wound healing by enhancing wound closure, tissue regeneration, and cellular interactions involved in repair processes.

This study observed that patients with androgenetic alopecia had significantly higher serum FABP4 levels compared to healthy controls, suggesting FABP4 may be involved in the condition's pathogenesis.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This study found that serum FABP4 levels were significantly higher in alopecia areata patients compared to healthy controls and may correlate with disease severity.

This study found that Aire‒/‒ mice spontaneously developed persistent AA-like lesions, highlighting a potential role for AIRE in hair follicle biology and pathogenesis of alopecia areata.

AUC and APL are distinct conditions needing careful clinical assessment.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

In this study, the rs4541843 G > A variant was found to be significantly associated with increased risk and severity of alopecia areata, as well as elevated expression of hsa-miR-182-5p, suggesting their potential as molecular markers for diagnosis and severity assessment.

This study reported that an ATRA-loaded nanostructured lipid carrier gel (ATRA-NLC-Gel) improved symptoms of alopecia areata in mice by enhancing transdermal drug delivery, reducing skin irritation, and promoting hair regrowth through targeted follicle enrichment and pathway activation.

In this study on mice with severe thermal skin burns, researchers found that administering 4-aminopyridine (4-AP) helped reduce inflammation and apoptosis, promoted angiogenesis, and accelerated wound healing by enhancing specific cellular behaviors and signaling pathways.

This report describes a rare case of papular atrichia in a 4-year-old girl, highlighting the absence of effective treatment to stimulate hair growth for this condition.

This study found that 4-aminopyridine significantly improves skin wound healing by enhancing various cellular and molecular processes, suggesting its potential for rapid translational development in wound treatment.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

This study observed that the rs231775 CTLA4 genetic variant was more prevalent in Alopecia Areata patients than controls, particularly among those with severe disease.

This review suggests that annurca apple extract, rich in polyphenols, may be a promising alternative for treating baldness, though further research is needed to clearly assess its effectiveness compared to existing treatments.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

The researchers reported that a 4-aminopyridine-loaded gel promoted wound healing and hair follicle regeneration in burn models, suggesting it might be a promising alternative to existing burn treatments.

This study found that the genetic variants rs231775 and rs3087243 of the CTLA4 gene are not associated with alopecia areata in the Mexican population analyzed.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This study found that A-FABP serum levels were significantly higher in male patients with androgenetic alopecia compared to controls, and the authors concluded that A-FABP could serve as a biomarker for early detection of this condition.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.